Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

This study tests whether adding a second immunotherapy drug (relatlimab) to nivolumab (a standard immunotherapy drug) before surgery helps reduce tumors more in people with high-risk basal cell carcinoma (BCC) — a type of skin cancer — that can be surgically removed. The goal is to see if the combination shrinks tumors more effectively before surgery than nivolumab alone. **You may be eligible if...** - You are 18 or older - You have been diagnosed with basal cell carcinoma confirmed by biopsy - Your BCC is "high-risk" (at least 20 mm on the head/neck, or at least 40 mm elsewhere) - Your cancer can be surgically removed, but surgery is expected to cause significant cosmetic or functional problems - You have not previously treated this BCC - Your physical health is reasonable (ECOG 0–1) **You may NOT be eligible if...** - You have already received treatment for this BCC - Your BCC cannot be removed with surgery - You have active autoimmune conditions or are on immunosuppressive medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.